急性呼吸窘迫综合征的代谢组学研究进展

Research progress on metabolomics of acute respiratory distress syndrome

急性呼吸窘迫综合征(ARDS)是一种临床上和生物学上的异质性临床综合征。考虑到由于病因、临床和分子表现形式的广泛差异而导致的ARDS异质性,目前的科学共识是,ARDS不是一种单一的疾病,而是一系列需要进一步研究以进行适当分类、识别和鉴定的病理生理过程。代谢组学是一个迅速发展的系统生物学领域,在作为跨学科平台的科学和医学领域取得了许多突破。代谢组学为ARDS诊断中生物标志物的发现和分析提供了重要的机遇,有望揭示ARDS背后的生物学过程,并在解决ARDS异质性和严重程度评估方面展现出巨大潜力。为此,本文对有关ARDS代谢组学的研究进行了阐述,并讨论了ARDS代谢组学研究的进展和遇到的主要障碍。

Acute respiratory distress syndrome(ARDS)is a clinically and biologically heterogeneous disease.Given the heterogeneity of ARDS due to the wide range of etiological,clinical,and molecular manifestations,the current scientific consensus is that ARDS is not a single disease,but rather a set of diseases that require further research to properly classify and identify.Metabonomics,as a rapidly developing field of systems biology,has made many breakthroughs in science and medicine as an interdisciplinary platform.Metabonomics provides an important opportunity for the discovery and analysis of biomarkers in the diagnosis of ARDS,which is expected to reveal the biological process behind ARDS and show great potential in solving the heterogeneity and severity assessment of ARDS.This review focuses on the literature of ARDS metabonomics and summarizes the progress of ARDS metabonomics research and the main obstacles.